pharma · Staphylococcal Skin Infections
Targanta Therapeutics
Targanta Netherlands B.V.
Targanta Netherlands is a pharma organization headquartered in EU. Primary therapeutic focus areas include Staphylococcal Skin Infections. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent recor
Cambridge, USA HQ
63 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Employees
- 63
- Programs
- 1
- Drugs
- 1
- Patents
- 0
oritavancin
Phase 2 · small molecule · Staphylococcal Skin Infections
oritavancin for Staphylococcal Skin Infections is a Phase 2 program (small_molecule) at Targanta Netherlands B.V. with 1 ClinicalTrials.gov record(s).
Internal code TAR-ORI-SD001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Targanta Netherlands B.V.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Staphylococcal Skin Infections
- Status
- completed
- Trials
- 1